Skip to main content
logo
Cidara Therapeutics, Inc. (CDTX)
Jan 7, 2026 - CDTX was delisted (reason: acquired by MRK)
221.38
+0.06 (0.03%)
Inactive · Last trade price on Jan 6, 2026

Cidara Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
-1.2823.2823.549.5712.07
Revenue Growth
--94.52%-0.91%-52.60%310.81%-42.30%
Gross Profit
-131.82-70.6-13.48-6.67-23.52-55.95
Operating Income
-159.91-91.22-27.06-21.9-42.26-71.85
Net Income
-184.74-169.83-22.93-33.58-42.47-74.87
Earnings Per Share
-11.11-26.75-5.25-9.61-16.20-36.03
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
420.02189.8335.7832.7359.6835.91
Total Debt
1.983.584.881.215.067.96
Net Cash (Debt)
418.04186.2530.931.5254.6227.95
Net Cash Growth
238.65%502.73%-1.96%-42.29%95.42%-27.48%
Net Cash Per Share
25.1529.337.079.0220.8313.45

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-132.94-176.53-22.43-28.47-25.23-54.41
Capital Expenditures
--0.13-0.51-0.12-0.04-0.19
Free Cash Flow
-132.94-176.66-22.94-28.59-25.27-54.6
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingSep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
---57.90%-28.40%-47.44%-
Operating Margin
--7154.43%-116.22%-93.20%-85.24%-595.42%
Pretax Margin
--13356.16%-107.65%-92.39%-85.67%-597.59%
Profit Margin
--13319.77%-98.49%-142.94%-85.67%-620.48%
FCF Margin
--13855.84%-98.51%-121.69%-50.98%-452.45%

Valuation
Chart
Fiscal YearCurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingAug '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
-230.623.082.311.717.28